The new capital will support expansion of the company’s Techstart Early Access Program, accelerate commercial operations in the United States, and drive the commercial launch of the instrument, it states. 

“The market is telling us it’s ready,” said Olle Ericsson, Co-Founder and CEO of Moleculent. “We are seeing surging demand from leading research institutions and pharmaceutical partners across both Europe and the US. With Rubicon joining ARCH and Eir Ventures, we now have a syndicate of builders with successful track records of scaling life science companies from breakthrough technology to global impact. This new funding allows us to move moreaggressively as we work to put this platform into the hands of the scientists decoding the cellular conversations that drive human disease.” 

Ole Dahlberg

As part of the financing, Ole Dahlberg, Managing Partner at Rubicon Healthcare Partners, has joined the Moleculent Board of Directors. Dahlberg brings more than 20 years of international management experience in the life sciences across start-ups and global companies. He has held leadership roles at Life Technologies and Qiagen and previously led Cell Biology and Sample Preparation at Thermo Fisher Scientific.  

“We have evaluated platforms across the life sciences tools landscape for years, and Moleculent stands out as truly category-defining,” said Dahlberg. “The company’s approach to directly mapping cell-cell communication has the potential to transform how researchers study disease and develop therapies. The science, the team, and the early traction with world-class research partners gave us the conviction to lead this round.”